The Expression of the SLIT-ROBO Family in Adult Patients with Acute Myeloid Leukemia

Archivum Immunologiae Et Therapiae Experimentalis
Aleksandra GołosAgnieszka Wierzbowska

Abstract

SLIT-ROBO is a ligand-receptor family of neuronal guidance cues that has been involved in pathological and physiological angiogenesis. SLIT-ROBO expression is altered in many tumours. However, no data exist about the role of the whole family in acute myelogenous myeloid leukemia (AML). Herein, we assessed the expression of all SLIT-ROBO family in bone marrow (BM) biopsy of AML patients and control group on both protein and RNA levels. The paraffin-embedded tissue blocks were subjected to immunohistochemistry for SLIT1, SLIT2, SLIT3, ROBO1, ROBO2, ROBO3, and ROBO4. Microvessel density (MVD) was evaluated by CD34 immunohistochemistry. An in silico analysis using The Cancer Genome Atlas data repository was conducted for assessment of RNA level. Acute myeloid leukemia patients were generally high expressers of ROBO1 and ROBO2 compared to the controls (p < 0.0001, p < 0.001, respectively). In contrast, low expression of SLIT1, SLIT2, and SLIT3 ligands has been noted more commonly in AML than in control BM samples (p < 0.0001, p = 0.003, and p = 0.001, respectively). ROBO4 expression correlated with MVD. The in silico analysis showed a poor prognostic value of high ROBO3 and low SLIT2 RNA levels (p = 0.0003 and p = 0.0008, respective...Continue Reading

References

Dec 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P B VermeulenL Y Dirix
Feb 19, 2000·Current Opinion in Neurobiology·K Brose, M Tessier-Lavigne
Nov 15, 2000·Genome Research·L Huminiecki, R Bicknell
Dec 10, 2002·International Journal of Cancer. Journal International Du Cancer·Alain LatilOlivier Cussenot
May 8, 2004·Developmental Cell·Uta GrieshammerGail R Martin
Nov 10, 2004·British Journal of Cancer·R E DickinsonF Latif
Jun 14, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Michael GörnEckart Laack
Jul 15, 2005·Nature·Peter Carmeliet, Marc Tessier-Lavigne
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hirotaka ItoHiroyuki Aburatani
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Federica PerroneSilvana Pilotti
Feb 3, 2007·Breast Cancer Research and Treatment·Bernd C SchmidRobert Zeillinger
Mar 28, 2008·Biochemical Society Transactions·Erhard Hohenester
Jun 25, 2009·Epigenetics : Official Journal of the DNA Methylation Society·Thomas L DunwellFarida Latif
Oct 6, 2009·American Journal of Obstetrics and Gynecology·Shulan MaSun-Wei Guo
Nov 11, 2009·Reproduction : the Official Journal of the Society for the Study of Fertility·Rachel E DickinsonW Colin Duncan
Jan 8, 2011·Cell Stem Cell·Stephanie Smith-BerdanE Camilla Forsberg
Jan 18, 2011·Developmental Cell·Alexander W KochAnne Eichmann
Apr 6, 2011·Histochemistry and Cell Biology·Cai Feng DaiJing Zheng
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 28, 2013·Nature Genetics·UNKNOWN Cancer Genome Atlas Research NetworkJoshua M Stuart
Jul 16, 2014·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Stephen M HewittEduardo Rosa-Molinar

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
light microscopy
flow cytometry
transfection
MDS
transfecting
fluorescence-activated cell sorting

Software Mentioned

Bloodspot
cBioPortal for Cancer Genomics
STATISTICA

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.